直击业绩会|安科生物回应战略投资“竞争对手”:希望借此加速切入长效生长激素赛道

每日经济新闻
11 Apr

日前,安科生物(SZ300009,股价8.01元,市值133.9亿元)披露了2024年年报,公司于报告期内实现营业收入约25.36亿元,同比减少11.51%;归属于上市公司股东的净利润约7.07亿元,同比减少16.56%。在产业竞争加剧、终端市场增长放缓的背景下,作为国内市场仅次于长春高新的生长激素生产厂商,安科生物近年来也在积极转型、拓展抗病毒、肿瘤治疗等领域以摆脱单一产品依赖。4月10日,在...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10